论文部分内容阅读
目的:观察光动力疗法联合不同激光及抗VEGF药物(Bevacizumab)治疗AMD的安全性和临床疗效。方法:对经直接或间接眼底镜、彩色眼底照相、荧光素眼底血管造影(FFA)、吲哚青绿血管造影(ICGA)和光相干断层扫描(OCT)检查确诊为AMD合并CNV的患者52例,年龄55～82岁,平均年龄68.2岁。最佳矫正视力在手动至0.2。先行PDT治疗,1周内在表面麻醉下行玻璃体腔内注射Bevacizumab1.25mg(0.05ml)。
Objective: To observe the safety and clinical efficacy of photodynamic therapy combined with different laser and anti-VEGF drugs (Bevacizumab) in the treatment of AMD. Methods: Fifty-two patients with AMD-combined CNV who were diagnosed by direct or indirect ophthalmoscopy, color fundus photography, fluorescein angiography (FFA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) 55 ~ 82 years old, average age 68.2 years old. The best corrected visual acuity was at manual to 0.2. The first PDT treatment, intravitreal injection of Bevacizumab 1.25mg (0.05ml) under the surface anesthesia within 1 week.